Drug Profile
Research programme: matrix metalloproteinase inhibitors - Procter & Gamble
Alternative Names: Matrix metalloproteinase inhibitors - Procter & Gamble; Research programme: MMP inhibitors - Procter & GambleLatest Information Update: 08 Feb 2006
Price :
$50
*
At a glance
- Originator Procter & Gamble
- Class
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 08 Feb 2006 No development reported - Preclinical for Osteoarthritis in USA (unspecified route)
- 08 Feb 2006 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 20 Apr 2001 Preclinical development for Osteoarthritis in USA (Unknown route)